Similarly, inhibiting ALKBH5 in melanoma enhances the efficacy of PD-1 blockade, patients with low expression of ALKBH5 are more likely to benefit from PD-1 blockade therapy (31). The gene discussed is PDCD1; the disease is melanoma.